유방암 환자의 항암화학요법으로 인한 말초신경병증과 삶의 질 = Chemotherapy-induced Peripheral Neuropathy and Quality of Life in Breast Cancer Patients

다국어 초록 (Multilingual Abstract)

Purpose: This study was performed to identify the levels of paclitaxel-containing chemotherapy-induced peripheral neuropathy (CIPN) in relation to quality of life (QOL) in patients with breast cancer. Methods: A total of 82 breast cancer patients with CIPN participated in this study. Data were collected through self-reported questionnaires containing three instruments by the European Organization for Research and Treatment of Cancer (EORTC), such as QLQ-C30 for health-related QOL, QLQ-BR23 for breast cancerrelated QOL, and QLQ-CIPN20 for CIPN. Scores from all three instruments were transformed into 0 to 100 scale. Data were analyzed using SPSS/WIN20 with descriptive statistics and Pearson’s correlations. Results: The mean score for each subscale of health-related QOL was 46.14 for global health status, 62.43 for functional scale, and 31.29 for symptom scale. The mean score for each subscale of breast cancer-related QOL was 56.55 for the functional scale and 42.06 for the symptom scale. Also, the CIPN"s mean score on the sensory scale was 30.42, 24.03 on the motor scale, and 22.70 on the autonomic scale. There were significant moderate correlations between QOLs and CIPN (r ranged from -.37 to .65). Conclusion: There is a need to develop interventions for breast cancer patients to enhance their quality of life and to alleviate chemotherapy-induced peripheral neuropathy.

목차 (Table of Contents)

• 서론
• 연구 방법
• 연구 결과
• 논의
• 결론
• REFERENCES

참고문헌 (Reference)

1 곽미경(Kwak, Mi Kyong), "항암화학요법으로 인한 암환자의 말초신경병증 관련 특성과 삶의 질" 대한종양간호학회 10 (10): 231-239, 2010

2 김정혜, "항암화학요법으로 인한 말초신경병증을 경험하는 대장암 환자의 삶의 질" 대한종양간호학회 11 (11): 254-262, 2011

3 Yun YH, "Validation of the Korean version of the EORTC QLQ-C30" 13 : 863-868, 2004

4 Lee J, "Toxicity and quality of life of Korean breast cancer patients treated with docetaxel-containing chemotherapy without primary G-CSF prophylaxis. Breast Cancer 2013"

5 Wolf SL, "The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy(CIPN)as measured by the EORTC QLQ-CIPN instrument, N06CA" 20 : 625-632, 2012

6 Postma TJ, "The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy : the QLQ-CIPN20" 41 : 1135-1139, 2005

7 Cavaletti G, "The chemotherapy-induced peripheral neuropathy outcome measures standardization study : from consensus to the first validity and reliability findings" 24 (24): 454-462, 2013

8 Fayers PM, "The EORTC QLQ-C30 scoring manual." European Organization for Research and Treatment of Cancer 2001

9 Shimozuma K, "Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy : N-SAS BC 02, a randomized clinical trial" 20 (20): 3355-3364, 2012

10 Ferguson T, "Taxane for adjuvant treatment of early breast cance"

11 Faul F, "Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses" 41 : 1149-1160, 2009

12 Kim HY, "Reliability and validity of the Korean version of the EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20" 10-12, 2013

13 Merli F, "Quality of life assessment in elderly patients with aggressive non-Hodgkin’s lymphoma treated with anthracycline-containing regimens" 89 (89): 973-978, 2005

14 Visovsky C, "Putting evidence into practice : evidence-based interventions for chemotherapyinduced peripheral neuropathy" 11 (11): 901-913, 2007

15 Tofthagen C, "Peripheral neuropathy in patients with colorectal cancer receiving oxaliplatin" 15 (15): 182-188, 2011

16 Sasane M, "Patient-reported outcomes in chemotherapy-induced peripheral neuropathy: a review" 8 (8): 15-21, 2010

17 National Cancer Information Center, "National cancer statistics"

18 Richardson PG, "Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib" 24 (24): 3113-3120, 2006

19 Tofthagen C, "Falls in persons with chemotherapy-induced peripheral neuropathy" 20 : 583-589, 2012

20 Clark PG, "Effects of reiki, yoga, or meditation on the physical and psychological symptoms of chemotherapyinduced peripheral neuropathy : a randomized pilot study" 17 (17): 161-171, 2012

21 Kirsner RS, "Earlier stage at diagnosis and improved survival among Medicare HMO patients with breast cancer" 19 : 1619-1624, 2010

22 Yun YH, "Cross-cultural application of the Korean version of the European Organization for Research and Treatment of Cancer(EORTC)Breast Cancer Specific Quality of Life Questionnaire(EORTC QLQ-BR23)" 12 (12): 441-445, 2004

23 Ocean AJ, "Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies" 12 : 619-662, 2004

24 Wampler MA, "Case report : painful peripheral neuropathy following treatment with docetaxel for breast cancer" 9 (9): 189-193, 2005

25 Kautio A, "Burden of chemotherapy-induced neuropathy : a cross-sectional study" 19 : 1991-1996, 2011